Staphylococcus aureus Bacteremia Secondary to Severe Erlotinib Skin Toxicity
- 1 January 2008
- journal article
- case report
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 9 (1), 59-60
- https://doi.org/10.3816/clc.2008.n.010
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Dermatologic side effects associated with the epidermal growth factor receptor inhibitorsJournal of the American Academy of Dermatology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2005
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and ManagementClinical Lung Cancer, 2003
- Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225British Journal of Dermatology, 2001
- Current and future management of serious skin and skin-structure infectionsAmerican Journal Of Medicine, 1996